Lataneau

Latanoprost, the active ingredient in Lataneau, is a Prostaglandin F2α analog presented as an ophthalmic solution for ocular use. It lowers intra‑ocular pressure and is used to manage open‑angle glaucoma and ocular hypertension in adults. GNH USA supplies Lataneau as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lataneau (Latanoprost) is a prostaglandin analog that reduces intra‑ocular pressure in glaucoma‑related conditions. - Open‑angle glaucoma: decreases intra‑ocular pressure to slow optic nerve damage. - Ocular hypertension: lowers elevated eye pressure to prevent progression to glaucoma. - Post‑surgical ocular pressure control: helps maintain target pressure after glaucoma surgery.

Latanoprost may cause a range of ocular and systemic reactions.

Common Side Effects: - Eye redness: mild conjunctival hyperemia. - Increased eyelash growth: longer, thicker lashes. - Iris pigmentation change: gradual darkening of eye colour. - Eye irritation: itching or foreign‑body sensation.

Serious or Rare Side Effects: - Severe eye inflammation: uveitis or iritis requiring medical attention. - Macular edema: swelling of the central retina. - Allergic reaction: swelling, rash, or difficulty breathing. - Ocular infection: signs of bacterial or fungal infection.

Before using Lataneau, consider the following safety measures. - Pregnancy: consult a healthcare provider as safety data are limited. - Breastfeeding: discuss potential risks with a physician. - Active ocular infection or inflammation: avoid use until resolved. - Contact lens wearers: remove lenses before instillation and wait at least 15 minutes before reinserting. - Systemic prostaglandin exposure: monitor for systemic effects. - Store at below 25°C: keep in the original container, protect from light and moisture.

Latanoprost can interact with other ocular or systemic agents.

Major Interactions (Avoid): - Other prostaglandin analog eye drops: additive IOP reduction may cause hypotony. - Systemic carbonic anhydrase inhibitors: may increase risk of ocular side effects.

Moderate Interactions (Monitor Closely): - Topical NSAID eye drops: may diminish Latanoprost efficacy. - Beta‑blocker eye drops: combined IOP‑lowering effect may require monitoring. - Anticholinergic agents: possible reduced outflow effect.